GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InSite Vision Inc (OTCPK:INSV) » Definitions » Cash Flow from Investing

InSite Vision (InSite Vision) Cash Flow from Investing : $-0.00 Mil (TTM As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is InSite Vision Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2015, InSite Vision spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, InSite Vision spent $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2015.


InSite Vision Cash Flow from Investing Historical Data

The historical data trend for InSite Vision's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InSite Vision Cash Flow from Investing Chart

InSite Vision Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.35 -19.68 16.37 2.91 4.72

InSite Vision Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.01 - -0.01 -

InSite Vision Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

InSite Vision's Cash Flow from Investing for the fiscal year that ended in Dec. 2014 is calculated as:

InSite Vision's Cash Flow from Investing for the quarter that ended in Jun. 2015 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InSite Vision  (OTCPK:INSV) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

InSite Vision's purchase of property, plant, equipment for the three months ended in Jun. 2015 was $-0.00 Mil. It means InSite Vision spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

InSite Vision's sale of property, plant, equipment for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

InSite Vision's purchase of business for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

InSite Vision's sale of business for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

InSite Vision's purchase of investment for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

InSite Vision's sale of investment for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

InSite Vision's net Intangibles purchase and sale for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

InSite Vision's cash from discontinued investing activities for the three months ended in Jun. 2015 was 0.00 Mil. It means InSite Vision paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

InSite Vision's cash from other investing activities for the three months ended in Jun. 2015 was $0.00 Mil. It means InSite Vision paid $0.00 Mil for other investing activities.


InSite Vision Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of InSite Vision's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


InSite Vision (InSite Vision) Business Description

Traded in Other Exchanges
N/A
Address
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
Executives
Louis Drapeau officer: Vice President and CFO C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., SUITE 210, NOVATO CA 94949
Brian Levy director
Anthony J Yost director C/O INSITE VISION, INC., 965 ATLANTIC AVENUE, ALAMEDA CA 94501
Timothy Mcinerney director
Craig A Tooman director
Coliseum Capital Management, Llc 10 percent owner 105 ROWAYTON AVENUE, ROWAYTON CT 06853
Timothy P Lynch director 919 NW BOND STREET, SUITE 204, BEND OR 97703
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Francis Wen-hou Chen director 1821 JONES STREET, SAN FRANCISCO CA 94109
Pinto Tv Gp Co Llc 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Matthew S Crawford 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192

InSite Vision (InSite Vision) Headlines

No Headlines